Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anaptysbio (ANAB) EBITDA (2016 - 2025)

Anaptysbio filings provide 10 years of EBITDA readings, the most recent being $49.5 million for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 322.79% year-over-year to $49.5 million, compared with a TTM value of -$13.6 million through Dec 2025, up 90.59%, and an annual FY2025 reading of -$13.6 million, up 90.59% over the prior year.
  • EBITDA hit $49.5 million in Q4 2025 for Anaptysbio, up from $15.2 million in the prior quarter.
  • The five-year high for EBITDA was $49.5 million in Q4 2025, with the low at -$46.5 million in Q2 2024.
  • Median EBITDA over the past 5 years was -$34.8 million (2022), compared with a mean of -$25.4 million.
  • The sharpest move saw EBITDA plummeted 6778.74% in 2022, then surged 322.79% in 2025.
  • Year by year, EBITDA stood at -$32.8 million in 2021, then rose by 21.7% to -$25.7 million in 2022, then crashed by 58.5% to -$40.7 million in 2023, then surged by 45.3% to -$22.2 million in 2024, then skyrocketed by 322.79% to $49.5 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at $49.5 million, $15.2 million, and -$38.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.